Monthly Prescribing Reference

Efzofitimod Misses Primary Endpoint in Pulmonary Sarcoidosis Trial

The study did not meet the primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48. Topline data were announced from a phase 3 trial evaluating efzofitimod in ...

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback.Company plans to submit IND in June 2026 for ...
Healio

More patients with sarcoidosis are steroid-free with 48-week efzofitimod vs. placebo

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients receiving efzofitimod vs. placebo were steroid-free with a stable/improved King ...

aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

Tyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C ...
Business Wire

Kinevant Sciences Announces First Patient Dosed in Phase 2 Study of Namilumab for the Treatment of Pulmonary Sarcoidosis (RESOLVE-Lung)

NEW YORK & BASEL, Switzerland--(BUSINESS WIRE)--Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare autoimmune and inflammatory diseases, today announced ...
Monthly Prescribing Reference

Efzofitimod Gets Fast Track Status for Pulmonary Sarcoidosis

Pulmonary Sarcoidosis Efzofitimod is a potential first-in-class selective modulator of neuropilin-2 that is designed to downregulate innate and adaptive immune responses in inflammatory disease states ...

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans ...
News Medical

Methotrexate found to be effective alternative to prednisone for pulmonary sarcoidosis

Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research published at the ATS 2025 International ...
Nasdaq

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters ...
Healio

Q&A: Early diagnosis, optimal treatment key for patients with pulmonary sarcoidosis

Please provide your email address to receive an email when new articles are posted on . A new review published in JAMA highlights the current diagnosis and treatment of pulmonary sarcoidosis. The ...

aTyr Pharma, Inc.: aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chron ...